HomeTRENDING NEWSDrug With a 30-Year Monopoly Is Target of State-Level Push to Curb... Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices By rogerjudd October 23, 2025 FacebookTwitterPinterestWhatsApp In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. Previous articleAlaska pilot seeks SCOTUS relief in case in which three beer cases led to forfeiture of $95K planeNext articleHoping to Grow in Europe, but Bogged Down by Red Tape latest articles Hurricane Melissa Forecast: What to Expect in the Caribbean and Florida Starring in Videos Is No Longer a Job Just for the Social Media Team 12-year-old Minneapolis church shooting survivor shot in head released from hospital DHS marks ‘one of the most violent days’ of Operation Midway Blitz with several arrests Trending stocks this week: Wall Street extends gains on softer inflation, trade optimism 5 out of 6 S&P 500 materials stocks beat EPS estimates this week: Earnings Scorecard explore more Hurricane Melissa Forecast: What to Expect in the Caribbean and Florida Starring in Videos Is No Longer a Job Just for the Social Media Team 12-year-old Minneapolis church shooting survivor shot in head released from hospital DHS marks ‘one of the most violent days’ of Operation Midway Blitz with several arrests Trending stocks this week: Wall Street extends gains on softer inflation, trade optimism 5 out of 6 S&P 500 materials stocks beat EPS estimates this week: Earnings Scorecard
